Meeting
2019 ASCO Annual Meeting
Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors.
Authors
Anan Abdelmoti Abu Rmilah Jr.
Mayo Clinic, Rochester, MN
Anan Abdelmoti Abu Rmilah Jr., Grace Lin Sr., Joerg Herrmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3033)
DOI
10.1200/JCO.2019.37.15_suppl.3033
Abstract #
3033
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese
Poster
2016 ASCO Annual Meeting
Frequency and risk factors for tyrosine kinase inhibitor–associated cardiotoxicity.
First Author: Peter J. Hurley
Poster
2014 ASCO Annual Meeting
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML.
First Author: Preetesh Jain
First Author: Ronald J. Rieder